CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

02nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

Investor Relations Archive Press releases

01/29/2020

CHEPLAPHARM’s successful institutional bond debut: 500 million euros of senior secured notes at 3.500% placed with institutional investors

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding, following its last capital market transaction in May…


more chevron_right
Investor Relations Archive

01/28/2020

CHEPLAPHARM announces pricing of Senior Secured Notes

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of 100.0%.


more chevron_right
Archive

01/23/2020

CHEPLAPHARM announces offering of Senior Secured Notes

Cheplapharm Arzneimittel GmbH has launched an offering of €400 million aggregate principal amount of senior secured notes due 2027.


more chevron_right
Archive Press releases

10/10/2019

CHEPLAPHARM strengthens its relationship with AstraZeneca by acquiring the global commercial rights to LOSEC®

AstraZeneca has agreed to sell the global commercial rights - excluding China, Japan, the U.S. and Mexico - to LOSEC® (omeprazole) and associated brands to CHEPLAPHARM. This is CHEPLAPHARM’s first…


more chevron_right
Archive

07/29/2019

Minister-President Schwesig visits CHEPLAPHARM

Schwerin/Greifswald (DE), 07/26/2019 – As part of her summer tour through Mecklenburg-Western Pomerania, Minister-President Manuela Schwesig stops by at the CHEPLAPHARM company headquarters in…


more chevron_right
Archive

06/19/2019

CHEPLAPHARM's third capital market transaction five times oversubscribed

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year. Offering additional 150 million euros Term Loan B…


more chevron_right
Archive

05/10/2019

Axia Best Managed Company Award goes to CHEPLAPHARM

Düsseldorf/Greifswald (DE), May 10, 2019 – CHEPLAPHARM Arzneimittel GmbH received the "Axia Best Managed Companies Award" (Axia BMC Award) yesterday. With the award and seal of quality, the audit and…


more chevron_right
Archive

03/25/2019

CHEPLAPHARM celebrates topping-out ceremony

Just in time with the arrival of spring, CHEPLAPHARM Arzneimittel GmbH is celebrating the topping-out ceremony for the extension building at its headquarters in the Hanseatic town of Greifswald…


more chevron_right
Archive

01/09/2019

By taking over the product rights for DORMICUM® and LEXOTAN®, CHEPLAPHARM closes the very successful fiscal year 2018

more chevron_right
Investor Relations Archive

11/23/2018

CHEPLAPHARM places additional € 300 million capital market loan in London with Institutional Investors

Following a successful roadshow with Institutional Investors in London, CHEPLAPHARM Arzneimittel GmbH was able to issue another loan (TLB market) in mid-November.


more chevron_right

Investor Relations topics

Back to top expand_less